Evaluation of efficacy of immunosuppressive therapy plus recombinant human thrombopoietin for children with severe aplastic anemia
10.3760/cma.j.issn.0578-1310.2017.07.011
- VernacularTitle: 免疫抑制治疗联合重组人血小板生成素对儿童重型再生障碍性贫血的效果评价
- Author:
Kang ZHOU
1
;
Chenxi LIU
;
Yang LI
;
Jianping LI
;
Huihui FAN
;
Li ZHANG
;
Liping JING
;
Guangxin PENG
;
Lei YE
;
Yuan LI
;
Lin SONG
;
Xin ZHAO
;
Wenrui YANG
;
Zhijie WU
;
Fang CHEN
;
Fengkui ZHANG
Author Information
1. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
- Publication Type:Clinical Trail
- Keywords:
Anemia, aplastic;
Thrombopoiesis;
Immunosuppression;
Child
- From:
Chinese Journal of Pediatrics
2017;55(7):523-528
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the therapeutic efficacy and safety of immunosuppressive therapy (IST) combined with recombinant human thrombopoietin (rhTPO) for severe aplastic anemia (SAA) in pediatric patients.
Method:A retrospective case-control study was conducted and the clinical data of 45 pediatric patients with de novo SAA admitted to the Anemia Diagnosis and Treatment Center of Chinese Academy of Medical Sciences & Blood Disease Hospital during the period from December 2009 to December 2014 were analyzed. Among them, 15 patients were treated with the regimen of IST together with rhTPO and 30 patients were given IST treatment only. The variation characteristics of the peripheral blood routine as well as the transfusion of blood products was dynamically observed, and the therapeutic efficacy was assessed respectively after 3, 6 and 12 months after the treatment. In the meantime, adverse effects related to rhTPO application were recorded. Thereafter, the statistics of the two groups were compared by non-parametric rank sum test.
Result:Among 45 pediatric patients, there were 26 male and 19 female, and the median age was 11 years (6-14). The number of patients received good hematological response(complete remission (CR) plus good partial response (GPR)) in the combinatory group versus vs. the IST group was 6 vs. 3 patients (χ2=3.906, P=0.048) at the 3rd month, 7 vs. 7 patients (χ2=1.568, P=0.210) at the 6th month, and 13 vs. 14 patients (χ2=6.667, P=0.01) at the 12th month respectively. For those achieved good hematological response at the 3rd month, the amount of platelets transfusion and red blood cells transfusion of the combined group were both less than that of the IST group during the period from the 10th to the 12th weeks (platelets transfusion: 1.4 U vs. 2.9 U, t=-3.523, P=0.002; red blood cells transfusion: 0.8 U vs. 2.6 U, t=-2.392, P=0.026). No serious adverse effect related to rhTPO application was observed in the IST combined with rhTPO group.
Conclusion:Application of rhTPO can improve the short-term therapeutic efficacy of IST for pediatric SAA, alleviate transfusion dependence, and has a good safety profile.
